All Studies Meta Analysis Recent:

Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study

Nag et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

May 2022

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Curcumin for COVID-19

14th treatment shown to reduce risk in February 2021

^*, now known with p = 0.000000046 from 26 studies.

Lower risk for mortality, ventilation, hospitalization, progression, recovery, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19early.org

In Silico study showing showing significant inhibitory potential of curcumin for omicron.

39 preclinical studies support the efficacy of curcumin for COVID-19:

17 In Vitro studies Bahun, Bormann, Boseila, Eleraky, Goc, Goc (B), Guijarro-Real, Kandeil, Leka, Marín-Palma, Mohd Abd Razak, Nittayananta, Septisetyani, Singh, Teshima, Wu, Zhang

1 In Vivo animal study Boseila

In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spike Note A, Nag, Moschovou, Kandeil, Singh (B), Boseila (and specifically the receptor binding domain Note B, Kant, Srivastava, Eleraky), M^pro Note C, Moschovou, Kandeil, Srivastava, Naderi Beni, Rajagopal, Rampogu, Sekiou, Singh, Winih Kinasih, Thapa, Bahun, Eleraky, Boseila, RNA-dependent RNA polymerase Note D, Singh (C), Eleraky, ACE2 Note E, Singh (B), Thapa, Alkafaas, nucleocapsid Note F, Hidayah, Suravajhala, and nsp10 Note G, Suravajhala proteins. In Vitro studies demonstrate inhibition of the spike Note A, Mohd Abd Razak (and specifically the receptor binding domain Note B, Goc (B)), M^pro Note C, Bahun, Guijarro-Real, Mohd Abd Razak, Wu, ACE2 Note E, Goc (B), and TMPRSS2 Note H, Goc (B) proteins. In Vitro studies demonstrate efficacy in Calu-3 Note I, Bormann, A549 Note J, Mohd Abd Razak, 293T Note K, Zhang, HEK293-hACE2 Note L, Nittayananta, Wu, 293T/hACE2/TMPRSS2 Note M, Septisetyani, and Vero E6 Note N, Bormann, Eleraky, Kandeil, Leka, Mohd Abd Razak, Nittayananta, Singh, Teshima, Marín-Palma cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants Kant, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells Marín-Palma, and alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress Zhang.

Important missing comments or errors? Let us know.

1. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

2. Bahun et al., Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols, Food Chemistry, doi:10.1016/j.foodchem.2021.131594.sciencedirect.com, doi.org.

3. Bormann et al., Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro, Viruses, doi:10.3390/v13101914.mdpi.com, doi.org.

4. Boseila et al., Throat spray formulated with virucidal Pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS CoV-2, European Journal of Pharmaceutics and Biopharmaceutics, doi:10.1016/j.ejpb.2024.114279.sciencedirect.com, doi.org.

5. Eleraky et al., Curcumin Transferosome-Loaded Thermosensitive Intranasal in situ Gel as Prospective Antiviral Therapy for SARS-Cov-2, International Journal of Nanomedicine, doi:10.2147/IJN.S423251.dovepress.com, doi.org.

6. Goc et al., Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants, European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022.akjournals.com, doi.org.

7. Goc (B) et al., Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions, PLOS ONE, doi:10.1371/journal.pone.0253489.plos.org, doi.org.

8. Guijarro-Real et al., Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity, Foods, doi:10.3390/foods10071503.mdpi.com, doi.org.

9. Hidayah et al., Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition, International Conference on Organic and Applied Chemistry, doi:10.1063/5.0197724.aip.org, doi.org.

10. Kandeil et al., Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2, Pathogens, doi:10.3390/pathogens10060758.mdpi.com, doi.org.

11. Kant et al., Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2023.2300060.tandfonline.com, doi.org.

12. Leka et al., In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds, Phytotherapy Research, doi:10.1002/ptr.7463.wiley.com, doi.org.

13. Marín-Palma et al., Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms, Molecules, doi:10.3390/molecules26226900.mdpi.com, doi.org.

14. Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.sagepub.com, doi.org.

15. Moschovou et al., Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein, International Journal of Molecular Sciences, doi:10.3390/ijms242115894.mdpi.com, doi.org.

16. Naderi Beni et al., In silico studies of anti-oxidative and hot temperament-based phytochemicals as natural inhibitors of SARS-CoV-2 Mpro, PLOS ONE, doi:10.1371/journal.pone.0295014.plos.org, doi.org.

17. Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552.sciencedirect.com, doi.org.

18. Nittayananta et al., A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity, Virology Journal, doi:10.1186/s12985-023-02282-x.biomedcentral.com, doi.org.

19. Rajagopal et al., Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach, Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x.springeropen.com, doi.org.

20. Rampogu et al., Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2, International Journal of Molecular Sciences, doi:10.3390/ijms23031771.mdpi.com, doi.org.

21. Sekiou et al., In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2, ChemRxiv, doi:10.26434/chemrxiv.12181404.v1.chemrxiv.org, doi.org.

22. Septisetyani et al., Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion, bioRxiv, doi:10.1101/2023.09.28.560070.biorxiv.org, doi.org.

23. Singh et al., Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M Pro protein - An in-silico and cell-based approach, Research Square, doi:10.21203/rs.3.rs-3888947/v1.researchsquare.com, doi.org.

24. Singh (B) et al., Computational studies to analyze effect of curcumin inhibition on coronavirus D614G mutated spike protein, The Seybold Report, doi:10.17605/OSF.IO/TKEXJ.ac.in, doi.org.

25. Singh (C) et al., Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104965.sciencedirect.com, doi.org.

26. Srivastava et al., Paradigm of Well-Orchestrated Pharmacokinetic Properties of Curcuminoids Relative to Conventional Drugs for the Inactivation of SARS-CoV-2 Receptors: An In Silico Approach, Stresses, doi:10.3390/stresses3030043.mdpi.com, doi.org.

27. Suravajhala et al., Comparative Docking Studies on Curcumin with COVID-19 Proteins, MDPI AG, doi:10.20944/preprints202005.0439.v3.preprints.org, doi.org.

28. Teshima et al., Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells, Natural Product Research, doi:10.1080/14786419.2023.2194647.tandfonline.com, doi.org.

29. Thapa et al., In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2, Makara Journal of Science, doi:10.7454/mss.v27i3.1609.ac.id, doi.org.

30. Winih Kinasih et al., Analisis in silico interaksi senyawa kurkuminoid terhadap enzim main protease 6LU7 dari SARS-CoV-2, Duta Pharma Journal, doi:10.47701/djp.v3i1.2904.ac.id, doi.org.

31. Wu et al., Potential Mechanism of Curcumin and Resveratrol against SARS-CoV-2, Research Square, doi:10.21203/rs.3.rs-2780614/v1.researchsquare.com, doi.org.

32. Zhang et al., Computational Discovery of Mitochondrial Dysfunction Biomarkers in Severe SARS-CoV-2 Infection: Unveiling Their Functions and Facilitating Drug Screening, Elsevier BV, doi:10.2139/ssrn.4677176.ssrn.com, doi.org.

a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.

b. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.

c. The main protease or M^pro, also known as 3CL^pro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting M^pro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.

d. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.

e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.

f. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.

g. Non-structural protein 10 (nsp10) serves as an RNA chaperone and stabilizes conformations of nsp12 and nsp14 in the replicase-transcriptase complex, which synthesizes new viral RNAs. Nsp10 disruption may destabilize replicase-transcriptase complex activity.

h. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.

i. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.

j. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.

k. 293T is a human embryonic kidney cell line that can be engineered for high ACE2 expression and SARS-CoV-2 susceptibility. 293T cells are easily transfected and support high protein expression.

l. HEK293-hACE2 is a human embryonic kidney cell line with high ACE2 expression and SARS-CoV-2 susceptibility. Cells have been transfected with a plasmid to express the human ACE2 (hACE2) protein.

m. 293T/hACE2/TMPRSS2 is a human embryonic kidney cell line engineered for high ACE2 and TMPRSS2 expression, which mimics key aspects of human infection. 293T/hACE2/TMPRSS2 cells are very susceptible to SARS-CoV-2 infection.

n. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.

Nag et al., 1 May 2022, India, peer-reviewed, 4 authors. Contact: anish.nag@christuniversity.in.

In Silico studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Curcumin All

Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study

Anish Nag, Ritesh Banerjee, Subhabrata Paul, Rita Kundu

Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

Background: Omicron (B.1.1.529), a variant of SARS-CoV-2 is currently spreading globally as a dominant strain. Due to multiple mutations at its Spike protein, including 15 amino acid substitutions at the receptor binding domain (RBD), Omicron is a variant of concern (VOC) and capable of escaping vaccine generated immunity. So far, no specific treatment regime is suggested for this VOC. Methods: The three-dimensional structure of the Spike RBD domain of Omicron variant was constructed by incorporating 15 amino acid substitutions to the Native Spike (S) structure and structural changes were compared that of the Native S. Seven phytochemicals namely Allicin, Capsaicin, Cinnamaldehyde, Curcumin, Gingerol, Piperine, and Zingeberene were docked with Omicron S protein and Omicron S-hACE2 complex. Further, molecular dynamic simulation was performed between Crcumin and Omicron S protein to evaluate the structural stability of the complex in the physiological environment and compared with that of the control drug Chloroquine. Results: Curcumin, among seven phytochemicals, was found to have the most substantial inhibitory potential with Omicron S protein. Further, it was found that curcumin could disrupt the Omicron S-hACE2 complex. The molecular dynamic simulation demonstrated that Curcumin could form a stable structure with Omicron S in the physiological environment. Conclusion: To conclude, Curcumin can be considered as a potential therapeutic agent against the highly infectious Omicron variant of SARS-CoV-2.

Author contributions A.N. conceived, designed the study & performed the experimentations; Primary data analysis & manuscript draft preparation were done by S.P. Secondary data analysis was done by RB and proof reading & manuscript finalisation was done by R.K. All authors read and approved the final manuscript. Declaration of competing interest Authors declare that there is no conflict of interest. Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi. org/10.1016/j.compbiomed.2022.105552.

References

Aliebrahimi, Montasser, Kouhsari, Ostad, Arab et al., Identification of phytochemicals targeting c-met kinase domain using consensus docking and molecular dynamics simulation studies, Cell Biochem. Biophys, doi:10.1007/s12013-017-0821-6

Choudhary, Malik, Tomar, Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach, Front. Immunol

Cs De Magalhães, Almeida, Barbosa, Dardenne, A dynamic niching genetic algorithm strategy for docking highly flexible ligands, Inf. Sci, doi:10.1016/j.ins.2014.08.002

Dedecker, O'brien, Fleming, Geiger, Jackson et al., The crystal structure of a hyperthermophilic archaeal TATA-box binding protein, J. Mol. Biol, doi:10.1006/jmbi.1996.0697

Desta, Porter, Xia, Kozakov, Vajda, Performance and its limits in rigid body protein-protein docking, Structure, doi:10.1016/j.str.2020.06.006

Dolgin, Omicron thwarts some of the world's most-used COVID vaccines, Nature

Du, Qian, Xue, Molecular simulation of oncostatin M and receptor (OSM-OSMR) interaction as a potential therapeutic target for inflammatory bowel disease, Front. Mol. Biosci

Fu, Tu, Ping, Zheng, Yang et al., Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors, Acta Pharmacol. Sin, doi:10.1038/s41401-020-00541-z

Greaney, Starr, Bloom, An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain, bioRxiv, doi:10.1101/2021.12.04.471236

Gupta, Vemula, Donde, Gouda, Behera et al., In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1751300

Harvey, Carabelli, Jackson, Gupta, Thomson et al., SARS-CoV-2 variants, spike mutations and immune escape, Nat. Rev. Microbiol, doi:10.1038/s41579-021-00573-0

He, Hong, Pan, Lu, Wei, SARS-CoV-2 Omicron variant: characteristics and prevention, MedComm, doi:10.1002/mco2.110

Jena, Kanungo, Nayak, Chainy Gbn, Dandapat, Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies, Sci. Rep, doi:10.1038/s41598-021-81462-7

Korber, Fischer, Gnanakaran, Yoon, Theiler et al., Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus, Cell, doi:10.1016/j.cell.2020.06.043

Kumari, Kumar, Open Source Drug Discovery Consortium, A. Lynn, g_ mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations, J. Chem. Inf. Model, doi:10.1021/ci500020m

Kushwaha, Singh, Prajapati, Shuaib, Gupta et al., Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: a molecular docking and MD simulation study, Microb. Pathog, doi:10.1016/j.micpath.2021.104954

Kutzner, Páll, Fechner, Esztermann, De Groot et al., More bang for your buck: improved use of GPU nodes for GROMACS 2018, J. Comput. Chem, doi:10.1002/jcc.26011

Li, Li, Hong, Wang, Fu et al., Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs, Briefings Bioinf, doi:10.1093/bib/bby130

Li, Nie, Wu, Zhang, Ding et al., SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape, Cell, doi:10.1016/j.cell.2021.02.042

Liu, Vanblargan, Bloyet, Rothlauf, Chen et al., Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization, Cell Host Microbe, doi:10.1016/j.chom.2021.01.014

Marín-Palma, Tabares-Guevara, Zapata-Cardona, Flórez-Álvarez, Yepes et al., Curcumin inhibits in vitro SARS-CoV-2 infection in Vero E6 cells through multiple antiviral mechanisms, Molecules, doi:10.3390/molecules26226900

Nag, Banerjee, Chowdhury, Venkatesh, Phytochemicals as potential drug candidates for targeting SARS CoV 2 proteins, an in silico study, Virus. Dis, doi:10.1007/s13337-021-00654-x

Nag, Paul, Banerjee, Kundu, In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools, Comput. Biol. Med, doi:10.1016/j.compbiomed.2021.104818

Pandurangan, Ochoa-Montaño, Ascher, Blundell, SDM: a server for predicting effects of mutations on protein stability, Nucleic Acids Res, doi:10.1093/nar/gkx439

Rao, Shetty, Evolutionary selectivity of amino acid is inspired from the enhanced structural stability and flexibility of the folded protein, Life Sci, doi:10.1016/j.lfs.2021.119774

Ren, Wang, Gao, Zhou, Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance, World J Clin Cases, doi:10.12998/wjcc.v10.i1.1

Ribaudo, Coghi, Yang, Ng, Mastinu et al., Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptorbinding domain (RBD), Nat. Prod. Res, doi:10.1080/14786419.2021.1925894

Richards, Lim, An analysis of packing in the protein folding problem, Q. Rev. Biophys, doi:10.1017/s0033583500002845

Schüttelkopf, Van Aalten, PRODRG: a tool for high-throughput crystallography of protein-ligand complexes, Acta Crystallogr. Sect. D Biol. Crystallogr, doi:10.1107/S0907444904011679

Singh, Chauhan, Pandit, Sinha, Gupta et al., The dual role of phytochemicals on SARS-CoV-2 inhibition by targeting host and viral proteins, Complementary Altern. Med, doi:10.1016/j.jtcme.2021.09.001

Tong, Shi, Zhang, Shi, Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa, Trav. Med. Infect. Dis, doi:10.1016/j.tmaid.2021.102252

Wang, Schmidt, Weisblum, Muecksch, Barnes et al., mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants, Nature, doi:10.1038/s41586-021-03324-6

Xue, Wang, Tu, Yang, Zheng et al., Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder, Phys. Chem. Chem. Phys, doi:10.1039/C7CP07869B

Xue, Yang, Wang, Zheng, Chen et al., What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation, ACS Chem. Neurosci, doi:10.1021/acschemneuro.7b00490

Yang, Lin, Xing, Zhang, Zhang et al., Structure-based discovery of novel nonpeptide inhibitors targeting SARS-CoV-2 Mpro, J. Chem. Inf. Model, doi:10.1021/acs.jcim.1c00355

Yang, Qin, Li, Tao, Zhou et al., Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information, Nucleic Acids Res, doi:10.1093/nar/gkv1230

Yang, Yu, Chang, Liang, Tso et al., Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function, Nat. Struct. Mol. Biol, doi:10.1038/s41594-021-00652-z

Yang, Zhang, Yang, Zhang, Wu et al., Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain, Chem. Biol. Drug Des, doi:10.1111/cbdd.13847

Zhang, Wu, Wu, Yang, Chen et al., SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance, Signal Transduct, Targeted Ther, doi:10.1038/s41392-021-00852-5

Zhu, Shi, Qin, Tao, Liu et al., Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery, Nucleic Acids Res, doi:10.1093/nar/gkr797

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0